Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

ABSTRACT:

Background

The EUMDS registry is an unique prospective, longitudinal observational registry enrolling newly diagnosed patients with lower-risk myelodysplastic syndrome (MDS) from 17 European countries from both university hospitals and smaller regional hospitals.

Objective

The aim of this study was to describe the usage and clinical impact of erythropoiesis-stimulating agents (ESAs) in 1696 patients enrolled between 2008 and 2014.

Methods

The effects of ESAs on outcomes were assessed using proportional hazards models weighting observations by propensity to receive ESA treatment within a subset of anaemic patients with or without a regular transfusion need.

Results

ESA treatment (median duration of 27.5 months, range 0-77 months) was administered to 773 patients

SUBMITTER: Garelius HK 

PROVIDER: S-EPMC5596334 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature